• Raphael Geminder, chairman of Kin Group, is spearheading the takeover bid for Pact Group Holdings.
    Raphael Geminder, chairman of Kin Group, is spearheading the takeover bid for Pact Group Holdings.
Close×

The board of Pact Group has told shareholders that Raphael Geminder’s takeover offer through Kin Group is too low, and advised them to reject the proposed deal.

Kin, which already owns 50.2 per cent of Pact, has offered 68c a share, but an independent expert hired by the directors, Kroll Australia, says the shares are worth between $1.06 and $1.51. The board has told shareholders that the offer made by Kin is “neither fair nor reasonable”.

In the letter to shareholders Pact director Michael Wachtel, who is a member of the independent board formed to deal with the unsolicited offer, labelled the move “opportunistic”, and said Kin was trying to gain full control of Pact “without paying a customary premium".

Wachtel also said the offer does not take into account Pact’s transformation strategy, with its $20m in cost reductions, nor its pending divestment of half its crate pooling and crate manufacturing business, which will reduce its leverage by $160m.

Geminder wants to take Pact off the ASX. It listed a decade ago, when its shares were trading for $3.80, more than five times the current value. The offer by Geminder, who is worth $1.3bn according to the Financial Review Rich List, values the company at $234m.

Food & Drink Business

Elixinol Wellness has completed the sale of its US business and reported a narrowed first half loss, with revenue up 5.8 per cent to $7.2 million and gross margin close to 10 per cent higher as the group concentrates on its Australian food and wellness brands.

Nourish Ingredients has completed a 10-tonne industrial production run of its animal-free dairy fat, Creamilux, at SD Guthrie International’s facilities in the Netherlands, under a partnership that gives the Australian company European manufacturing capacity without building its own plant.

Bubs Australia has received permanent regulatory authorisation from the US FDA for its three infant formula products – Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential.